# Immunogenicity and Safety of 23-valent Pneumococcal Polysaccharide Vaccine

> **NCT05477693** · PHASE4 · COMPLETED · sponsor: **Sinovac Biotech Co., Ltd** · enrollment: 1800 (actual)

## Conditions studied

- Pneumococcal Infections

## Interventions

- **BIOLOGICAL:** Experimental 23-valent PPV
- **BIOLOGICAL:** Control 23-valent PPV

## Key facts

- **NCT ID:** NCT05477693
- **Lead sponsor:** Sinovac Biotech Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-10-25
- **Primary completion:** 2023-04-10
- **Final completion:** 2023-04-10
- **Target enrollment:** 1800 (ACTUAL)
- **Last updated:** 2023-09-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05477693

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05477693, "Immunogenicity and Safety of 23-valent Pneumococcal Polysaccharide Vaccine". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05477693. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*